Sirolimus for the treatment of complicated vascular anomalies in children

Pediatric Blood and Cancer

Volumn 57, Issue 6, 2011, Pages 1018-1024

  Hammill, Adrienne M ^a,b   Wentzel, Marysue ^a   Gupta, Anita ^a,b   Nelson, Stephen ^c   Lucky, Anne ^a,b   Elluru, Ravi ^a,b   Dasgupta, Roshni ^a,b   Azizkhan, Richard G ^a,b   Adams, Denise M ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

Author keywords

Kaposiform hemangioendothelioma; Kasabach Merritt phenomenon; Lymphatic malformation; Rapamycin; Sirolimus; Vascular anomalies; Vascular malformations

Indexed keywords

COTRIMOXAZOLE; IMMUNOGLOBULIN; PENTAMIDINE; RAPAMYCIN;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; CHILD; CLINICAL ARTICLE; CONGENITAL BLOOD VESSEL MALFORMATION; CONTROLLED STUDY; DIFFUSE MICROCYSTIC LYMPHATIC MALFORMATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH STATUS; HEMANGIOENDOTHELIOMA; HUMAN; HYPERCHOLESTEROLEMIA; INFANT; KAPOSIFORM HEMANGIOENDOTHELIOMA; KASABACH MERRITT SYNDROME; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NEUTROPENIA; PNEUMOCYSTOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TREATMENT FAILURE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME; VASCULAR MALFORMATIONS;

EID: 80052651179     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23124     Document Type: Article

References (37)

1. Enjolras O, Wassef M, Chapot R. Color atlas of vascular tumors and vascular malformations. New York City, NY: Cambridge University Press; 2007. pp. 1-11.
2. Dompmartin A, Acher A, Thibon P, et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 2008; 144: 873-877.
3. Patel DV. Gorham's disease or massive osteolysis. Clin Med Res 2005; 3: 65-74.
4. Dompmartin A, Vikkula M, Boon LM. Venous malformation: Update on aetiopathogenesis, diagnosis and management. Phlebology 2010; 25: 224-235.
5. Reinhardt MA, Nelson SC, Sencer SF, et al. Treatment of childhood lymphangiomas with interferon-alpha. J Pediatr Hematol Oncol 1997; 19: 232-236.
6. Dickerhoff R, Bode VU. Cyclophosphamide in non-resectable cystic hygroma. Lancet 1990; 335: 1474-1475.
7. Turner C, Gross S. Treatment of recurrent suprahyoid cervicofacial lymphangioma with intravenous cyclophosphamide. Am J Pediatr Hematol Oncol 1994; 16: 325-328.
8. Sidbury R. Update on vascular tumors of infancy. Curr Opin Pediatr 2010; 22: 432-437.
9. Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100: 1377-1386.
10. Lyons LL, North PE, Mac-Moune Lai F, et al. Kaposiform hemangioendothelioma: A study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 2004; 28: 559-568.
11. Brown SH, Jr., Neerhout RC, Fonkalsrud EW. Prednisone therapy in the management of large hemangiomas in infants and children. Surgery 1972; 71: 168-173.
12. Bartoshesky LE, Bull M, Feingold M. Corticosteroid treatment of cutaneous hemangiomas: How effective? A report on 24 children. Clin Pediatr (Phila) 1978; 17: 625, 629-638.
13. Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-Merritt phenomenon: A retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002; 24: 459-462.
14. Fahrtash F, McCahon E, Arbuckle S. Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine. J Pediatr Hematol Oncol 2010; 32: 506-510.
15. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998; 132: 527-530.
16. Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004; 114: 1231-1236.
17. Hu B, Lachman R, Phillips J, et al. Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin d. J Pediatr Hematol Oncol 1998; 20: 567-569.
18. Hauer J, Graubner U, Konstantopoulos N, et al. Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach-Merritt phenomenon using four-drug regimen. Pediatr Blood Cancer 2007; 49: 852-854.
19. Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-537.
20. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37: 19-24.
21. Shirazi F, Cohen C, Fried L, et al. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo Lymphat Res Biol 2007; 5: 233-236.
22. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
23. Perry B, Banyard J, McLaughlin ER, et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo Arch Dermatol 2007; 143: 504-506.
24. Tan WH, Baris HN, Burrows PE, et al. The spectrum of vascular anomalies in patients with PTEN mutations: Implications for diagnosis and management. J Med Genet 2007; 44: 594-602.
25. Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008; 5: 357-361.
26. Blatt J, Stavas J, Moats-Staats B, et al. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010; 55: 1396-1398.
27. Falger JC, Mueller T, Arbeiter K, et al. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006; 10: 565-569.
28. Sindhi R, Seward J, Mazariegos G, et al. Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatr Transplant 2005; 9: 391-397.
29. Schachter AD, Benfield MR, Wyatt RJ, et al. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Pediatr Transplant 2006; 10: 914-919.
30. Debelenko LV, Perez-Atayde AR, Mulliken JB, et al. D 2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma. Mod Pathol 2005; 18: 1454-1460.
31. Le Huu AR, Jokinen CH, Ruben BP, et al. Expression of PROX1, lymphatic endothelial nuclear transcription factor, in kaposiform hemangioendothelioma and tufted angioma. Am J Surg Pathol 2010; 34: 1563-1573.
32. Makinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001; 20: 4762-4773.
33. Salameh A, Galvagni F, Bardelli M, et al. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 2005; 106: 3423-3431.
34. Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007; 71: 771-777.
35. Flores MV, Hall CJ, Crosier KE, et al. Visualization of embryonic lymphangiogenesis advances the use of the zebrafish model for research in cancer and lymphatic pathologies. Dev Dyn 2010; 239: 2128-2135.
36. Kobayashi S, Kishimoto T, Kamata S, et al. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007; 98: 726-733.
37. Adams DM, Wentzel MS. The role of the hematologist/oncologist in the care of patients with vascular anomalies. Pediatr Clin North Am 2008; 55: 339-355, viii.